Investigating Carriage, Contamination, Antimicrobial Resistance and Assessment of Colonization Risk Factors of *Campylobacter spp.* in Broilers from Selected Farms in Thika, Kenya

Mwajuma K. Abubakar[1*], Anne W. T. Muigai[2], Perpetual Ndung'u[3] and Samuel Kariuki[4]

[1]*Department of Medical Microbiology, College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.*
[2]*Department of Botany, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.*
[3]*Department of Medical Laboratory Sciences, College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.*
[4]*Center for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.*

Authors' contributions

This work was carried out in collaboration among all authors. Authors MKA and SK contributed equally in the development of the study idea, study design and acquisition of data. Authors MKA, SK, AWTM and PN all contributed in data analysis and interpretation of results. Manuscript development, its revision, writing and approval of paper contributed by authors MKA, SK, AWTM and PN. All authors read and approved the final manuscript.

Article Information

Original Research Article

ABSTRACT

Aims: To investigate carriage and contamination rates of chicken broiler meat, the factors that are associated with *Campylobacter spp.* colonization and its phenotypic and genotypic antimicrobial resistance from Thika small-scale poultry farms.
Study Design: The study design was cross-sectional and laboratory based, it employed simple random sampling across 18 small-scale farms.

_____

Corresponding author: E-mail: mwajumaabu@gmail.com;

Site and Duration of Study: The study was conducted between August and December 2017 at Thika sub-county, a town located 42 Km North East of Nairobi.
Methodology: One hundred and eighty five cloaca swab samples from live broilers and 158 neck swab samples from broiler carcasses were collected. Isolates were obtained by plating method using mCCDA, conventional methods and duplex PCR were used for the isolation and identification of *Campylobacter* species.
Results: Carriage prevalence was at 15.67%, significantly (*P* = .000) lower than contamination prevalence detected at 30.37%. While the overall *Campylobacter spp.* prevalence was 22.45%. Risk of *Campylobacter* colonization in the flock doubled in feeding broilers with chicken waste and older poultry, at (OR: 2.57, 95% CI: 0.19 - 34.47) and (OR: 2.00, 95% CI: 0.312 - 12.84) respectively. The *Campylobacter spp.* were resistant (*P* < .05) against Ciprofloxacin, Streptomycin, and Trimethoprim between carriage and contamination. MDR was 79.22%; XDR was 12.98% while no PDR recorded.
Conclusion: Broilers in Thika region are potentially important source of human infection and possible continuity of infection from the threat posed by *Campylobacter* carrier broilers. Presence of *sulI* and *dhfr* genes with high resistance observed for quinolones, sulfonamides, ß-lactams and trimethoprim, thus posing a major public health problem for consumers of poultry products.

1. INTRODUCTION

Poultry are major reservoirs of *Campylobacter spp.* and thus the main source of human *campylobacter*iosis [1]. *Campylobacter jejuni* and *Campylobacter coli* are the two major species known to dominate in human *campylobacter*iosis [2]. This disease is the most common cause of bacterial gastroenteritis, with symptoms ranging from abdominal pain, fever, mild watery diarrhea to bloody stools [3]. Reiter's syndrome and Guillian-Barre syndrome may occur as complications in severe cases [4]. The epidemiology of *Campylobacter spp.* in poultry production is still incompletely understood [5]. For more than a decade, there has been a major debate on whether vertical or horizontal transmissions are responsible for introduction of *Campylobacter* into flocks [5,6]. *Campylobacter* invade chicken early in life through various risk factors, as several studies have shown revealing potential *Campylobacter* introduction channels into broilers houses as well as factors contributing to the introduction have been studied [7]. Risk factors that have been associated with *Campylobacter* ability to colonize chicken include, but are not limited to; contaminated drinking water, administration of antibiotics, [8,9]; poor hygiene [10]; and old age of the flock [11]. Despite good hygiene practices, broiler slaughter poses a risk of cross-contamination and bacteria spread from the gastrointestinal tract to the carcass and subsequently to humans [12,13]. The ISO method 10272-2 for food legislation purposes is the official method for detection and enumeration of *Campylobacter spp.* while the molecular methods are not considered "confirmatory" tests [14].

In Africa, epidemiology of *Campylobacter* (especially for *C. jejuni*, *C. coli* and *C. lari*) infection have not been sufficiently addressed due to lack of national surveillance program and most of the *Campylobacter spp.* estimate reports are mainly from laboratory-based surveillance of pathogens responsible for diarrhea [15]. However, few prevalence studies conducted on *Campylobacter* enteritis in five African states showed a range of between 5 to 20% [15]. In Brazil, contamination of chicken carcasses with *Campylobacter spp.* from various slaughter-houses was 16.8% where *C. jejuni* isolation was higher (93.8%) than *C. coli* [16]. While a Sri Lanka study [17] samples purchased at retail shops detected much higher *Campylobacter spp.* prevalence (59%) with *C. coli* being the most frequently isolated species at 69.2% than *C. jejuni* at 30.7%.

Recent study in Nairobi reported the following *Campylobacter* prevalence; between 33-44% for broiler chicken, 60% for indigenous chicken farms and 64% for chicken meat retailers from Dagoretti and Kibera informal settlement areas [18].

Although *Campylobacter* infections are self-limiting, in severe cases of prolonged enteritis and septicemia, antimicrobial treatment is often needed [19]. Fluoroquinolones and macrolides are often the drugs of choice to treat human

*campylobacter*iosis. However, over the years studies have reported increases in resistance to Fluoroquinolones and Macrolides of *Campylobacter spp.* despite they being drugs of choice for its treatment [20]. A study from Northern Tunisia showed very high resistance rates detected against Quinolones, Tetracycline and Macrolides ranging from 88.6% to 100% [21].

Albeit Thika is one of the largest broiler suppliers to the capital, Nairobi, there is scanty information regarding this pathogen. To the best of our knowledge, this is the first study to document carriage, contamination and resistance prevalence including resistance genes of *Campylobacter* in broilers from small-scale farmers in Thika. In addition, the study evaluated factors that are associated with *Campylobacter* colonization consequently might have contributed to carriage, contamination and antibiotic resistance in this region.

2. MATERIALS AND METHODS

2.1 Sample Collection

Thika is an industrial town located at 42 Km North East of Nairobi where intense broiler farming is widely practiced. Nairobi city is a major market for the poultry products. The study design was cross-sectional and laboratory based, it employed simple random sampling method where 343 samples were collected across 18 farms in Landless location between August and December 2017. One hundred and eighty five cloaca samples from live poultry while 158 neck swabs from broiler carcasses were collected for determination of carriage status and contamination respectively. Swabs with modified charcoal-cefoperazone-deoxycholate agar (mCCDA) were used for sampling and further transported in a box with ice packs to the laboratory where analysis were done immediately.

2.2 Culture, Isolation and Identification of *Campylobacter*

Samples were directly plated onto mCCDA and incubated at 42ºC for 48 h in a microaerophilic environment (5% O_2, 10% CO_2 and 85% N_2) generated by candles. Suspect *Campylobacter* colonies by colonial characteristics were further identified by conventional methods (Gram stain, Oxidase, Catalase and hippurate tests), then emulsified in Eppendorf tubes with sterile distilled water ready for DNA extraction.

2.3 Identification by PCR

Polymerase Chain Reaction (PCR) assay was performed to identify *Campylobacter* genus prior to the duplex PCR to identify *C. jejuni* and *C. coli.* The *cadF* gene was selected as Universal forward primer, FU, (Amplicon size; 101 - 120) and reverse primer, R1, (Amplicon size; 478 - 497) described previously [22]. R2 (Amplicon size; 542 – 561) and R3 (Amplicon size; 818 – 837) for identification of *C. coli* and *C. jejuni* respectively [23].

DNA extraction by boiling for 25 min in a water bath at 100ºC followed by centrifugation for 15 min at 15000 rpm was done and supernatant used for the analysis. Reaction tubes contained a final reaction volume of 25 µl comprised of 4 µl duplex PCR master mix, Betaine 1 µl, 1 µl primer (for each of the four primers) and 1 µl DNA template. Amplification reactions were carried out in a thermocycler under the following conditions: initial denaturation for 3 min at 95ºC 1 cycle; 32 cycles denaturation for 30s at 94ºC, annealing at 43ºC for 30s, extension for 30s at 72ºC and a final extension for 5 min at 72ºC. The PCR products analyzed by electrophoresis on stained 1.5% agarose gel under UV light.

Levene's test of equal variance (t-test) was used to determine the statistical difference between carriage and contamination prevalence at P = .05.

Table 1. Primer sequences for identification of cadF (*Campylobacter* genus), aspK (*C. coli*) and hipO (*C. jejuni*) genes used in duplex polymerase chain reaction

Primer	Primer sequence ('5 – 3')[I]	Product size, bp	Identification	Reference
FU	TTGAAGGTAATTTAGATATG	400	*Campylobacter* spp.	Konkel et al.
R1	CTAATACCTAAAGTTGAAAC	400	*Campylobacter* spp.	Konkel et al.
R2	TTTATTAACTACTTCTTTTG	461	*C. coli*	Shams S et al.
R3	ATATTTTTCAAGTTCATTAG	737	*C. jejuni*	Shams S et al.

[I] *43ºC annealing temperature for all the primers*

2.4 Analysis of Risk Factors

Six variables were tested; hygiene practices (good, fair or poor), age of poultry (< 3 weeks or > 3 weeks), type of feed (kitchen waste, chicken feed or both), antibiotics used (tetracycline or none), rinse procedure (Bucket or running water) and slaughter area (open grounds, slaughter house or near poultry house), used to evaluate risk factors associated with *Campylobacter* colonization. Analyzed by odds ratio (OR) at 95% Confidence Interval (CI) and Chi square tests at *P* = .05.

2.5 Antimicrobial Susceptibility Test

Antimicrobial Susceptibility Tests (ASTs) of *Campylobacter* species were performed against 12 antimicrobial agents; Ampicillin 10 μg (AMP), Gentamicin 10 μg (CN), Tetracycline 30 μg (TE), Erythromycin 15 μg (E), Chloramphenicol 30 μg (C), Trimethoprim 1.25 μg (W), Sulphamethoxazole 23:75 μg (RL), Nalidixic Acid 30 μg (NA), Ofloxacin 5 μg (OFX), Kanamycin 30 μg (K), Streptomycin 10μg (S) and Ciprofloxacin 5μg (CIP) were used for this analysis based on the commonly used antibiotics in Kenya. Disk diffusion method [24] was carried out recommended by the Clinical Laboratory Standards Institute (CLSI, 2012) and European Union Committee for Antimicrobial Susceptibility Testing (EUCAST, 2017)). Mueller Hinton Agar number 2 (MHA-II) was used with sterile 5% defibrinated sheep blood to grow a lawn of the bacterial isolate from freshly prepared 0.5 McFarland inoculated on the MH-II and eventually impregnated with antimicrobial disks and incubated under microaerophilic conditions for 48 h at 42ºC, according to a previous study [25].

Lists of antimicrobial breakpoints from the Centre for Disease Control & Prevention (CDC), European Centre for Disease Control (ECDC), the European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clinical Laboratory Standards Institute (CLSI) and the United States Food and Drug Administration (FDA). Multi drug resistant (MDR) was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories, extensively drug resistant (XDR) was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories and pan drug resistant (PDR) was defined as non-susceptibility to all agents in all antimicrobial categories [26]. These were used to categorize the isolates susceptibility and resistance as MDR, XDR or PDR from the measured zones of inhibition.

Statistical difference between carriage and contamination resistance was determined by Levene's test for equality of variance (t-test) *P* = < .05 followed by a non-parametric test (Mann Whitney U test) using a null hypothesis that stated; Distribution of antimicrobial agent is the same across the farms at significance level of 5% and 10%.

2.6 Determination of Resistance Genes

The highly resistant isolates against the various agents were selected for the characterization of their respective resistance genes (R-genes). Trimethoprim (*dhfr* gene), Sulfamethoxazole, (*sulI* gene) and Nalidixic Acid (*gryA* gene) R-genes were characterized at 126bp, 223bp and 620bp respectively. There were no R-genes in Nalidixic Acid while characterization for Ampicillin was not done. Reaction tubes contained a final reaction volume of 25 μl comprised of; 4 μl PCR master mix 18 μl PCR water, Betaine 1 μl, 2 μl primer and 1 μl DNA template. Amplification reactions for *dhfr* and *gryA* genes in a thermocycler were under the following conditions; initial denaturation for 4 min at 95ºC, 30 cycles denaturation for 1 min at 94ºC, annealing at 60ºC for 1 min, extension for 50s at 72ºC and a final extension for 5min at 72ºC. Same conditions applied for *sulI* gene except for annealing which was at 65ºC. The PCR products were analyzed by electrophoresis in stained 1.5% agarose gel under UV light.

Nalidixic Acid resistance using *gyr*A F- 5' GCTCTTGTTTTAGCTTGATGCA-3'and R-'5 TTGTCGCCATCCTACAGCTA-3' with annealing temperature of 50ºC was used to detect PCR reaction product of 620bp.

Sulfamethoxazole R-genes were detected using primer set F- 5'CGCACCGGAAACAT CGCTGCAC 3' and R- 5' TGAAGTTCCGCC GCAAGGCTCG 3' to amplify *sulI* gene with annealing temperature of 65ºC to detect PCR reaction product of 223bp.

Trimethoprim R-genes were detected using primer set F-5' CATGGTTGGTTC GCTAAACTGC3' and R- 5'GAGGTTGTGG TCATTCTCTGGAAATA 3' to amplify *dhfr* gene with annealing temperature of 60ºC to detect PCR reaction product of 126bp.

The PCR conditions were; denaturation at 95ºC for 4 min, 33 cycles with denaturation at 94ºC for 1 minute, annealing at varying temperatures; extension at 72ºC for 50 seconds, and a final extension at 72ºC for 5 min. The separation of PCR products were done by gel electrophoresis on Ethidium Bromide stained 1.5% agarose gel. (Vaishnavi et al. 2015).

C. jejuni ATCC 33560 and *C. coli* ATCC 33559 were used as positive controls while *E. coli* ATCC 25922 as negative control.

3. RESULTS

3.1 Carriage Prevalence

This study recorded overall *Campylobacter* prevalence of 22.45%, 30 of the *Campylobacter spp*. confirmed by PCR while the rest 47 were positive by conventional methods. Test for equality of variances (t-test) P = .05 was used to determine significant difference between isolates confirmed by PCR and isolates identified by conventional methods where: ($T_{6.150}$ = 1.902, *P* <.05 at *P* = .11).

Carriage recorded a prevalence of 15.67%, Six (20.68%) of these confirmed by PCR and the remaining 23 (12.43%) by conventional methods. Isolation prevalence of the different *Campylobacter spp*. was 44.8%, 41.4%, 6.9% and 6.9% for *C. jejuni*, *C. coli*, mixed species and other *Campylobacter spp*. respectively.

3.2 Contamination Prevalence

Contamination recorded a prevalence of 30.37% where the statistical difference between carriage and contamination prevalence was at *P* = .000. C*. jejuni* was the predominant *Campylobacter* spp. at 41.6% followed by *C. coli* at 33.3%, mixed species at 10.4% and other *Campylobacter spp.* at 14.6%. The statistical difference of *C. jejuni* and *C. coli* between carriage and contamination was at *P* = .000.

3.3 Associated Risk Factors

All factors showed increased risk of *Campylobacter* colonization in the flock apart from two; hygiene practices and feeding the broilers with combination of chicken feed and kitchen waste. The highest risk was feeding broilers with kitchen waste and age of poultry which doubled the risk of *Campylobacter* colonization in the flock (OR: 2.57, 95% CI: 0.19-34.47, *P* = .46) and (OR: 2.00, 95% CI: .312-12.84, *P* = .46) respectively. Followed by

slaughtering in the open ground (OR: 1.86, 95% CI: 0.28-12.31, *P* = .51) then slaughtering around the poultry house (OR: 1.25, 95% CI: 0.20-7.61, *P* = .80).

3.4 Antimicrobial Susceptibility Tests

The isolates showed increased resistance against Ampicillin, Nalidixic Acid, Sulfamethoxazole and Trimethoprim at 67.5%, 61%, 89.6% and 93.5% respectively. Isolates under Tetracycline and Chloramphenicol showed low resistance both at 15.6% with isolates under Gentamycin presenting the lowest resistance at 1.7%. Statistical difference of resistance between carriage and contamination was at; *P* = .01 in Sulfamethoxazole, *P* = .01 in Streptomycin and *P* = .000 at Ciprofloxacin. Among the six variables using Tetracycline in their broiler flock as growth promoters and prevention of infections recorded OR: 0.875 95% CI: 0.96-7.952 *P* = .96.

The Mann Whitney U test was conducted in two categories, first category; *Campylobacter spp*. with very high resistance at *P* = .05 which included Ampicillin, Nalidixic acid, Sulfamethoxazole and Trimethoprim. From these, only Sulfamethoxazole (*P* = .00) null hypothesis was rejected. Second category; the other eight remaining antimicrobial agents tested with levels of significance of *P* = .05 followed by *P* = .1. Streptomycin, Ciprofloxacin and Ofloxacin recorded the same *P* values from the two different levels of significance at *P* = .01, *P* = .00 and *P* = .05 respectively therefore their null hypothesis were rejected in both levels. Gentamycin (P = .07) null hypothesis was only rejected at P = .1 level of significance.

There was higher resistance prevalence of *C. jejuni* than *C. coli* (Table 2) in all the antimicrobial agents except Erythromycin, Nalidixic Acid and Ampicillin. The highest resistance of *C. jejuni* was 91.4% and 85.7% against Trimethoprim and Sulfamethoxazole respectively; Chloramphenicol had the lowest resistance prevalence (17.1%) in *C. jejuni*. While in *C. coli* Nalidixic Acid, was highest (80%) followed by Ampicillin (72%) and the lowest resistance was against Kanamycin and Chloramphenicol both at 12%.

The antibiotic susceptibility profile was studied to detect and profile MDR, XDR and PDR bacteria from Thika. MDR prevalence was 79.22% from this 36.06% represented MDR in carriage while MDR in contamination was much higher at 63.93%. In addition, MDR for *C. jejuni*, *C. coli*,

Table 2. Number and percentage resistance spectra of the 77 *Campylobacter* spp. isolates against 12 antimicrobial agents tested

Antibiotic Name	No. of resistant *Campylobacter* in carriage	No. of resistant *Campylobacter* in contamination	No. of resistant *C. jejuni*	No. of resistant *C. coli*	No. of resistant mixed species	No. of resistant of other *Campylobacter spp.*	Overall Resistant *Campylobacter spp.* isolates
AMP	22/29 (75.9%)	30/48 (62.5%)	24/35 (68.6%)	18/25 (72%)	5/8 (62.5%)	6/9 (66.7%)	52/77 (67.5%)
CN	9/29 (31%)	4/48 (8.3%)	5/35 (14.3%)	6/25 (24%)	1/8 (12.5%)	1/9 (11.1%)	13/77 (1.7%)
S	17/29 (58.6%)	8/48 (16.7%)	13/35 (37.1%)	9/25 (36%)	1/8 (12.5%)	1/9 (11.1%)	25/77 (32.5%)
K	10/29 (34.5%)	10/48 (20.8%)	9/35 (25.7%)	3/25 (12%)	0/8 (0%)	2/9 (22.2%)	20/77 (25.9%)
TE	8/29 (27.6%)	4/48 (8.3%)	7/35 (20%)	4/25 (16%)	1/8 (12.5%)	1/9 (11.1%)	12/77 (15.6%)
C	4/29 (13.8%)	8/48 (16.7%)	6/35 (17.1%)	3/25 (12%)	0/8 (0%)	2/9 (22.2%)	12/77 (15.6%)
E	10/29 (34.5%)	13/48 (27.1%)	9/35 (25.7%)	8/25 (32%)	2/8 (25%)	3/9 (33.3%)	23/77 (29.9%)
NA	19/29 (65.5%)	28/48 (58.3%)	17/35 (48.6%)	20/25 (80%)	7/8 (87.5%)	7/9 (77.8%)	47/77 (61%)
CIP	13/29 (44.8%)	7/48 (14.6%)	12/35 (34.3%)	6/25 (24%)	1/8 (12.5%)	1/9 (11.1%)	20/77 (25.9%)
OFX	9/29 (31%)	10/48 (20.8%)	10/35 (28.6%)	7/25 (28%)	0/8 (0%)	2/9 (22.2%)	19/77 (24.7%)
RL	22/29 (75.9%)	47/48 (97.9%)	30/35 (85.7%)	15/25 (60%)	8/8 (100%)	9/9 (100%)	69/77 (89.6%)
W	27/29 (93.1%)	45/48 (93.8%)	32/35 (91.4%)	15/25 (60%)	8/8 (100%)	8/9 (88.9%)	72/77 (93.5%)

mixed species of *C. jejuni*/ *C. coli* and for other *Campylobacter spp*. was 44.26%, 32.78%, 13.11% and 9.83%% respectively. Isolates exhibiting XDR was 12.98%; with a 50/50 prevalence for both carriage and contamination isolates. The XDR distribution in the species was *C. jejuni* (50%); *C. coli* (40%), Other *Campylobacter spp*. (10%) and none for mixed species. Six isolates were found to be "just resistant" by the fact that the isolates were non-susceptible to only two antimicrobial agents. Thirty three percent represented resistant isolates in carriage while 66.66% represented the resistant isolates in contamination, with even distribution of 33.33% in *C. jejuni*, *C. coli* and other *Campylobacter spp*. while there was no isolates recorded for mixed species and no PDR isolates detected.

3.5 Resistance Genes Characterization

The *dhfr* gene was the most prevalent with seventeen R-genes compared to ten from the *sulI* gene. There was 50% prevalence of the R-genes across the 18 sampled farms; Farm 18 had the highest prevalence of 40% of the resistance genes (only *dhfr* genes) while majority of the farms had just 3.70% prevalence. No R-genes were found in Nalidixic Acid-resistant isolates (*gryA* gene) while in Trimethoprim-resistant isolates characterization was not done. Farm 1 had two isolates while Farm 16 had one isolate carrying both *dhfr* and *sulI* genes. Distribution of *Campylobacter spp.* for *dhfr* gene was 17.64%, 23.52%, 29.41% and 29.41% for *C. jejuni*, *C. coli*, mixed species and other *Campylobacter spp*. respectively. While *sulI* gene recorded 30% for *C. jejuni*, 30% for *C. coli*, 30% for other *Campylobacter spp*. and only 10% for mixed species.

4. DISCUSSION

Thika sub-county is one of the largest broiler meat suppliers to Kenya's capital city Nairobi, where fried chicken is the fastest growing business thus, increasing the demand of broiler meat without knowledge of the thermophilic bacteria that may come with it. This study recorded an overall *Campylobacter* prevalence of 22.45%. Unlike other studies in the sub-Saharan African countries, they recorded up to 47-68% [27,28]. Which might be due to the small number of broiler farms sampled, a difference in size of commercial flocks, or a difference in sampling unit or even the testing methods.


Fig. 1. Graph pattern of sample collection distribution across 18 farms in Thika sub-County

Table 3. Percentage prevalence of positive *Campylobacter spp*. isolated per farm across the 18 sampled farms in Thika

Farm No.	Contamination		Carriage		Total no. of samples
	No. of positive samples	% Prevalence	No. of positive samples	% Prevalence	
1	10/12	83.33%	4/11	36.36%	23
2	1/20	5%	2/10	20%	30
3	No sample	-	0/10	0%	10
4	1/4	25%	3/9	33.33%	11
5	No sample	-	0/10	0%	10
6	No sample	-	0/5	0%	5
7	No sample	-	4/16	25%	16
8	No sample	-	6/16	37.5%	16
9	No sample	-	2/5	40%	5
10	No sample	-	3/3	100%	3
11 (a)	4/16	25%	1/7	14.28%	23
11 (b)	0/17	0%	0/6	0%	23
12	7/20	35%	No sample	-	20
13	0/10	0%	No sample	-	10
14	3/19	15.79%	No sample	-	19
15	0/3	0%	1/11	9.09%	14
16	4/12	33.33%	No sample	-	12
17	No sample	-	3/61	4.92%	61
18	18/25	72%	0/5	0%	30
TOTAL	48/158		29/185		343

P = .01, P = .00 and P = .05 respectively therefore their null hypothesis were rejected in both levels. Gentamycin (P = .07) null hypothesis was only rejected at P = .1 level of significance

**Resistance, Pan drug, Multi drug and Extensively drug resistance profiling**

Fig. 2. Antibiogram profile depicting antimicrobial susceptibility test (R, PDR, MDR and XDR) for *Campylobacter spp.* in carriage and contamination isolate

Distribution of *dhfr* and *sull* genes in carriage and contamination by species

Fig. 3. Chart depicting DHFR gene and sull gene distribution of *Campylobacter* species in carriage and contamination

dhfr and sulI resistance genes profiling across the farms

Fig. 4. Resistance genes profiling of *DHFR* genes and SULI genes across the 18 sampled farms

Recording carriage prevalence of 15.67% corroborating results from Ethiopia [29] that detected *Campylobacter* carriage with 18.41% prevalence in the Oromia region of the country and in 2013, 21.97% prevalence of *Campylobacter* from cloacal swabs was isolated in Italy [30]. In contrast, 42.5% prevalence of chickens of various breeds by cloacal swabs was recorded from a study in Tanzania [31] and as high as 100% prevalence of *Campylobacter* in cloacal swabs was also found by direct counting on two types of agar in Brazil [32]. Further, *Campylobacter* spp. in carriage cases from the present study were identified; 44.8%, 41.4%, 6.9% and 6.9% for *C. jejuni*, *C. coli*, mixed species and other *Campylobacter spp.* respectively.

These results are similar to results reported by various studies; where reports of the prevalence of *C. jejuni* is usually higher than that of *C. coli*. Of the three species, *C. jejuni* predominates, with *C. coli* and *C. lari* infrequently recovered from the intestinal tract of poultry [33].

Farm 17 had the highest number of samples collected but with the least *Campylobacter* isolation prevalence at 4.9% in carriage cases. Contrary to Farm 10, which had, the lowest number of samples collected had 100% (3/3) *Campylobacter* isolation prevalence.

With 30.37% contamination prevalence (doubling carriage prevalence), this study recorded a higher contamination prevalence in comparison to few other studies that identified much lower prevalence; 21.7% in retail raw chicken meat tested in Ethiopia [34], and 21.9% of commercial chicken carcasses swabbed in Ghana [35].

However, much lower than the prevalence in a 2018 study a contamination prevalence of 91.07% in broilers was found in peri-urban areas of Nairobi [36] and 85.3% contamination prevalence was recorded in chicken meat from Nairobi tested less than 24hours after slaughter from supermarkets and butcheries [37]. *Campylobacter spp.* identification for contamination cases from this study revealed that *C. jejuni* was more predominant (41.6%) than *C. coli* (33.3%), these results corroborated with results from southern Brazil where samples from the broiler slaughtering process recorded *C. jejuni* as the most predominant species at 72% and 38% for *C. coli*. Similarly, *C. jejuni* is responsible for over 95% of the diagnosed cases of *campylobacter*iosis as discussed earlier in Gonsalves' work in 2016. Notably, samples might contain multiple *Campylobacter* species, suggesting mixed colonization [38].

Farm 1 had highest number of contamination cases (83.3%) with 66.6% *C. coli* and 33.3% *C.*

jejuni, with other *Campylobacter spp.* at only 10% species isolation prevalence.

Consistent with prevalence of and risk factor for *Campylobacter* in France [39], the present study showed hygiene practices in Thika farms could contribute to a reduction in *Campylobacter* colonization, a factor found to have the lowest risk in this study. Feeding the broilers with kitchen waste and age of poultry doubled the risk of *campylobacter* colonization in the flock followed by slaughtering in the open ground then slaughtering around the poultry house. On the other hand, a combination of the chicken feed and kitchen waste showed a much-reduced risk compared to as when the broilers were fed on either of the two feeds. The farmers seemed to maintain good standards of hygiene practices apart from a few cases that did not raise the level of risk as usually expected.

Campylobacter infections cause gastroenteritis which is typically self-limiting the most important treatment is to avoid dehydration. Antibiotics treatment is usually needed in the most severe and persisting infections or pregnant women, young children, the old as well as immunocompromised patients [40,41]. There is strong evidence to support the observation the fluoroquinolone use in food animals is associated with increased numbers of infections with resistant strains of *Campylobacter* in humans [42]. Interestingly, Australian livestock does not utilize fluoroquinolones and as a result, *Campylobacter* isolates from this region have negligible levels of resistance to fluoroquinolones, which in turn correspond to low resistance levels in human isolates [43]. November 30, 2018 reports; Canada took a major step to stop antibiotic resistance on farms by implementing new regulations for access to antibiotics for farm animals, starting December 1, 2018 farmers in Canada will have access to 300 animal drugs only if they obtain a prescription from a veterinarian (https://qz.com/1480983/antibiotic-resistance-on-farms-could-be-slowed-by-canadas-new-regulations/.

Generally, there was high resistance prevalence in this study and even higher resistance in isolates against Ampicillin, Nalidixic Acid, Sulfamethoxazole and Trimethoprim at 67.53%, 61.03%, 89.61% and 93.50% respectively (Table 2). These results are in accordance with resistance investigation of *Campylobacter* isolates from Kenyan chicken [44] where high

resistance (>70%) was found in Nalidixic Acid, the same was observed in China [45].This wide-spread resistance to Nalidixic Acid corroborated reports on *Campylobacter* from different food animals/products in other countries [46,47]. In contrast, [48] reported lower Nalidixic Acid resistance rates (26%) for *Campylobacter* recovered from humans with diarrhea in Western Kenya in 2006. Similarly, high resistances of various proportions of Trimethoprim-Sulfamethoxazole [48,49] have been reported in Kenya. These Ampicillin-resistant isolates results are also consistent with [50] in South Korea, recorded 88.9% Ampicillin resistance in all the *C. coli* isolated in ducks in 2014 and a similar trend in 2015 was recorded (75.7%) in Tanzania [51]. Gallay and colleagues [52] found the proportion of resistance to Ampicillin increased among the groups of patients in that study. Ampicillin is of clinical interest because at times is used for the treatment of severe *campylobacter*iosis. There was moderate resistance from the 77 *Campylobacter* isolates against Ciprofloxacin (25.97%), Kanamycin (25.97%), Ofloxacin (24.67%), Erythromycin (29.87%) and Streptomycin (32.46%) (Table 2). Unlike many studies with high fluoroquinolones resistance [50,53,54], Ciprofloxacin and Ofloxacin resistance was much lower in this study, while no resistance to fluoroquinolones was found in Tanzania [55]. Generally, Macrolides are now considered the optimal antibiotic for treatment of *Campylobacter* infections; however, resistance to macrolides in human isolates in some countries is becoming a major public health concern. The macrolide resistance among *Campylobacter* strains has remained low and stable level for a long while. However, there is also evidence in some parts of the world that resistance rate to Erythromycin, and other macrolides in these bacteria are slowly increasing [56].

Much lower resistance in this study was recorded against Tetracycline 15.6%, Chloramphenicol 15.6% and Gentamycin 1.7%. The Tetracycline results corroborate the results by Brooks and others from Western Kenya in 2006, where 18% prevalence was obtained, contrary to this, 10 years later Nguyen and colleagues recorded >70% resistance against Tetracycline.

The Mann-Whitney U test rejected the hypothesis that distribution of Sulfamethoxazole, Streptomycin, Ciprofloxacin and Ofloxacin are the same across the farms at $P = .05$ level of significance, also rejected the same hypothesis

in Gentamycin, Streptomycin, Ciprofloxacin and Ofloxacin at *P* = .01 level of significance.

There was generally higher resistance prevalence in *C. jejuni* than in *C. coli* (Table 2) in all the antimicrobial agents except for Erythromycin, Nalidixic Acid and Ampicillin. The highest resistance in *C. jejuni* was 91.4% and 85.7% were recorded as the highest resistances against Trimethoprim and Sulfamethoxazole respectively; Chloramphenicol had the lowest resistance prevalence (17.1%) against *C. jejuni*. While Nalidixic Acid was highest (80%) followed by Ampicillin (72%) and the lowest resistance was in Kanamycin and chloramphenicol both at 12% against *C. coli* (Table 2). However, [57] reported low level of multidrug resistance in *C. jejuni* from broilers of the member states of the EU.

MDR prevalence in the present study was 79.22% from this 36.06% represented MDR in carriage while MDR in contamination was much higher at 63.93%. In addition, MDR for *C. jejuni*, *C. coli*, mixed species and for Other *Campylobacter spp*. was 44.26%, 32.78%, 13.11% and 9.83% respectively. In contrast, (40% *C. jejuni* and 69.9% *C. coli*) are comparable to those reported in other countries [58-60]. Isolates exhibited 12.98% XDR; with a 50/50 prevalence for both carriage and contamination isolates, species distribution was 50% *C. jejuni*, 40% *C. coli*, Other *Campylobacter spp*. (10%) and none for mixed species. Six isolates were found to be "just resistant" by the fact that the isolates were non-susceptible to only two antimicrobial agents. Thirty three percent (33.33%) represented resistant isolates in carriage while 66.66% represented the isolates in contamination, there was even distribution of 33.33% amongst *C. jejuni*, *C. coli* and other *Campylobacter spp*. while there was no isolates recorded for mixed species of *C. jejuni* and *C. coli*. There were no PDR isolates profiled in this study. These results are consistent with MDR observed in the majority of the tested isolates (94%) in a study conducted by Wang and colleagues, [61]. However 4.5% isolates were pan susceptible to all antimicrobials tested in Tanzania, according to Kashoma and colleagues.

Trimethoprim, *dhfr* gene and Sulfamethoxazole, *sulI* gene were characterized at 126bp in 17 isolates and at 223bp in 10 isolates respectively. No R-genes were found in Nalidixic Acid (*gryA* gene at 620bp) while in Ampicillin the

characterization was not done. R-genes conferring resistance in the other antimicrobial agents against *Campylobacter spp*. were not investigated due to lack of enough resources faced by the study.

5. CONCLUSION

The prevalence results suggested that Thika has low broiler *Campylobacter* infection and that carriage prevalence was lower than contamination prevalence. These findings suggest that should the farmers in Thika stop feeding their broilers with kitchen waste; and slaughtering the broilers at relatively younger age, the broilers would be at a lower risk of *Campylobacter* colonization. High level of resistance against Nalidixic acid, Ampicillin, Sulfamethoxazole and Trimethoprim as well as multidrug and extensively drug resistance were recorded in this study while no PDR isolates were recorded. The R-genes analysis was of significance since the results corroborated results from the phenotypic resistance analysis of the *Campylobacter* isolates observed in the antimicrobial susceptibility tests. The resistance results of especially ß-lactams and quinolones is indication for the need to strengthen implementation of control procedures and antibiotic regulations to reduce antibiotic resistance. Thika broilers are potentially important source of human infection, awareness best achieved by educating the public and training farmers on best practices.

CONSENT

All authors declare that written informed consent was obtained from the participating farmers before sample collection and for publication of the research findings.

ETHICAL APPROVAL

All authors hereby declare that principles of laboratory animal care (NIH publication No. 85-23, revised 1985) were followed. All experiments have been examined and approved by the Kenya Medical Research Institute – Scientific Ethical Review Unit (KEMRI-SERU) and Center for Microbiology - Scientific Steering Committee (CMR-SSC) under code: KEMRI/SERU/CMRP00056/3506.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Silva J, Leite D, Fernandes M, Mena C, Gibbs PA, Teixeira P. *Campylobacter* spp. as a foodborne pathogen: a review. Frontiers in microbiology 2011;2(200).
2. Rouger A, Tresse O ,Zagorec M Bacterial contaminants of poultry meat: Sources, species, and dynamics. Microorganisms. 2017;5(3):50.
3. Ecdc E. The European Union summary report on trends and sources of zoonoses, zoonotic agents and foodborne outbreaks in 2011. EFSA J. 2013;11(4):3129.
4. Boysen L, Rosenquist H, Larsson JT, Nielsen EM, Sørensen G, Nordentoft S, Hald T. Source attribution of human *campylobacter*iosis in Denmark. Epidemiology & Infection. 2014;142(8):1599-1608.
5. Cox NA, Richardson LJ, Maurer JJ, Berrang ME, Fedorka-Cray PJ, Buhr RJ, Byrd JA, Lee MD, Hofacre CL ,O'Kane PM. Evidence for horizontal and vertical transmission in *Campylobacter* passage from hen to her progeny. Journal of Food Protection. 2012;75(10):1896-1902.
6. Sahin O, Morishita TY, Zhang Q, *Campylobacter* colonization in poultry: Sources of infection and modes of transmission. Animal Health Research Reviews. 2002;3(2):95-105.
7. Chowdhury S, Sandberg M, Themudo GE , Ersbøll AK. Risk factors for *Campylobacter* infection in Danish broiler chickens. Poultry Science. 2012;91(10):2701-2709.
8. Refregier-Petton J, Rose N, Denis M, Salvat G. Risk factors for *Campylobacter* spp. contamination in French broiler-chicken flocks at the end of the rearing period. Preventive Veterinary Medicine. 2001;50(1-2):89-100.
9. Ansari-Lari M, Hosseinzadeh S, Shekarforoush SS, Abdollahi M, Berizi E. Prevalence and risk factors associated with *Campylobacter* infections in broiler flocks in Shiraz, southern Iran. International Journal of Food Microbiology. 2011;144(3):475-479.
10. Evans SJ, Sayers AR. A longitudinal study of *Campylobacter* infection of broiler flocks in Great Britain. Preventive Veterinary Medicine. 2000;46(3):209-223.
11. Bouwknegt M, Van de Giessen AW, Dam-Deisz WDC, Havelaar AH, Nagelkerke NJD, Henken AM. Risk factors for the presence of *Campylobacter* spp. in dutch broiler flocks. Preventive Veterinary Medicine. 2004;62(1):35-49.
12. Tang M, Zhou Q, Zhang J, Yang X, Gao Y. Prevalence and characteristics of *Campylobacter* throughout the slaughter process of different broiler batches. Frontiers in Microbiology. 2018;9(2092).
13. Althaus D, Zweifel C, Stephan R. Analysis of a poultry slaughter process: Influence of process stages on the microbiological contamination of broiler carcasses. Italian Journal of Food Safety. 2017;6(4).
14. Gharst G, Oyarzabal OA, Hussain SK. Review of current methodologies to isolate and identify *Campylobacter* spp. from foods. Journal of microbiological Methods. 2013;95(1):84-92.
15. Oberhelman RA, Taylor DN. *Campylobacter* infections in 4 developing countries. I. Nachamikin and MJ Blaser (eds.). 2000;249(139-154).
16. Hungaro HM, Mendonça RCS, Rosa VO, Badaró ACL, Moreira MAS, Chaves JBP. Low contamination of *Campylobacter* spp. on chicken carcasses in Minas Gerais state, Brazil: Molecular characterization and antimicrobial resistance. Food Control. 2015;51(15-22
17. Kottawatta K, Van Bergen M, Abeynayake P, Wagenaar J, Veldman K, Kalupahana R. *Campylobacter* in broiler chicken and broiler meat in Sri Lanka: Influence of

semi-automated vs. wet market processing on *campylobacter* contamination of broiler neck skin samples. Foods. 2017;6(12):105.

18. Carron M, Chang YM, Momanyi K, Akoko J, Kiiru J, Bettridge J, Chaloner G, Rushton J, O'Brien S, Williams N, Fèvre EM ,Häsler B. *Campylobacter*, a zoonotic pathogen of global importance: Prevalence and risk factors in the fast-evolving chicken meat system of Nairobi, Kenya. PLoS Neglected Tropical Diseases. 2018;12(8):1-18.
DOI: 10.1371/journal.pntd.0006658

19. Guévremont E, Nadeau É, Sirois M, Quessy S. Antimicrobial susceptibilities of thermophilic *Campylobacter* from humans, swine, and chicken broilers. Canadian Journal of Veterinary Research. 2006; 70(2):81.

20. WoŹNiak A, Wieliczko A. *Campylobacter* coli isolated from poultry in Poland. Bull Vet Inst Pulawy. 2011;55(51-54).

21. Gharbi M, Béjaoui A, Ben Hamda C, Jouini A, Ghedira K, Zrelli C, Hamrouni S, Aouadhi C, Bessoussa G, Ghram A. Prevalence and antibiotic resistance patterns of *Campylobacter* spp. isolated from broiler chickens in the north of Tunisia. BioMed Research International; 2018.

22. Konkel ME, Gray SA, Kim BJ, Garvis SG, Yoon J. Identification of the enteropathogens *Campylobacter jejuni* and *Campylobacter coli* based on the cadF virulence gene and its product. Journal of Clinical Microbiology. 1999;37(3):510-517.

23. Shams S, Bakhshi B, Moghadam TT. In silico analysis of the cadF gene and development of a duplex polymerase chain reaction for species-specific identification of *Campylobacter jejuni* and *Campylobacter coli.* Jundishapur Journal of Microbiology. 2016;9(2).

24. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. American Journal of Clinical Pathology. 1966; 45(4_ts):493-496.

25. Matuschek E, Brown DFJ, Kahlmeter G. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine micro-biology laboratories. Clinical Microbiology and Infection. 2014;20(4):O255-O266.

26. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012;18(3):268-281.

27. Ewnetu D, Mihret A. Prevalence and antimicrobial resistance of *Campylobacter* isolates from humans and chickens in Bahir Dar, Ethiopia. Foodborne Pathogens and Disease. 2010;7(6):667-670.

28. Komba EVG. Human and animal thermophilic *Campylobacter* infections in East African countries: Epidemiology and antibiogram. Biomedical Journal of Scientific and Technical Research. 2017; 1(5):1-10.
DOI: 10.26717/BJSTR.2017.01.000411

29. Mekkonen Y, Brena MC, Christley R, Bettridge JM, Collins M, Dessie T, Tessema TS. Detection of *Campylobacter* carriage rate in different poultry production systems in Ethiopi; 2013;

30. Marotta F, Garofolo G, Di Donato G, Aprea G, Platone I, Cianciavicchia S, Alessiani A, Di Giannatale E. Population diversity of *Campylobacter jejuni* in poultry and its dynamic of contamination in chicken meat. BioMed Research International; 2015.
DOI: 10.1155/2015/859845

31. Chuma IS, Nonga HE, Mdegela RH, Kazwala RR. Epidemiology and RAPD-PCR typing of thermophilic *campylobacter*s from children under five years and chickens in Morogoro Municipality, Tanzania. BMC Infectious Diseases. 2016; 16(1):692.

32. Gonsalves CC, Borsoi A, Perdoncini G, Rodrigues LB, do Nascimento VP. *Campylobacter* in broiler slaughter samples assessed by direct count on mCCDA and Campy-Cefex agar. Brazilian Journal of Microbiology. 2016;47(3):764-769.
DOI: 10.1016/j.bjm.2016.04.025

33. Shane SM. *Campylobacter* infection of commercial poultry. Revue Scientifique et Technique de l'OIE. 2000;19(2):376-395.
DOI: 10.20506/rst.19.2.1224

34. Dadi L, Asrat D. Prevalence and anti-microbial susceptibility profiles of thermotolerant *Campylobacter* strains in retail raw meat products in Ethiopia. Ethiopian Journal of Health Development. 2008;22(2):195-200.

35. Karikari AB, Obiri-Danso K, Frimpong EH, Krogfelt KA. Multidrug resistant

Campylobacter in faecal and carcasses of commercially produced poultry*;* 2016.

36. Lydia MM, Jackson NO, Florence KM. Prevalence and risk factors for *Campylobacter* infection of chicken in peri-urban areas of Nairobi, Kenya*.* Journal of Dairy, Veterinary & Animal Research. 2018;7(1):22-28.
DOI: 10.15406/jdvar.2018.07.00184

37. Osano O, Arimi SM. Retail poultry and beef as sources of *Campylobacter jejuni.* East African Medical Journal. 1999;76(3): 141-143.

38. Ugarte-Ruiz M, Gómez-Barrero S, Porrero MC, Alvarez J, Garcia M, Comeron MC, Wassenaar TM, Dominguez L. Evaluation of four protocols for the detection and isolation of thermophilic *Campylobacter* from different matrices*.* Journal of Applied Microbiology. 2012;113(1):200-208.

39. Allain V, Chemaly M, Laisney MJ, Rouxel S, Quesne S, Le Bouquin S. Prevalence of and risk factors for *Campylobacter* colonisation in broiler flocks at the end of the rearing period in France*.* British Poultry Science. 2014;55(4):452-459.

40. Tam CC, Rodrigues LC, Petersen I, Islam A, Hayward A, O'brien SJ. Incidence of Guillain-Barré syndrome among patients with *Campylobacter* infection: A general practice research database study*.* The Journal of Infectious Diseases 2006; 194(1):95-97.

41. Pacanowski J, Lalande V, Lacombe K, Boudraa C, Lesprit P, Legrand P, Trystram D, Kassis N, Arlet G, Mainardi JL. *Campylobacter* bacteremia: Clinical features and factors associated with fatal outcome*.* Clinical Infectious Diseases. 2008;47(6):790-796.

42. Gupta A, Nelson JM, Barrett TJ, Tauxe RV, Rossiter SP, Friedman CR, Joyce KW, Smith KE, Jones TF, Hawkins MA. Antimicrobial resistance among *Campylobacter* strains, United States, 1997–2001. Emerging Infectious Diseases. 2004;10(6):1102.

43. Cheng AC, Turnidge J, Collignon P, Looke D, Barton M, Gottlieb T. Control of fluoro-quinolone resistance through successful regulation, Australia*.* Emerging Infectious Diseases. 2012;18(9):1453.

44. Nguyen TNM, Hotzel H, Njeru J, Mwituria J, El-Adawy H, Tomaso H, Neubauer H, Hafez HM. Antimicrobial resistance of *Campylobacter* isolates from small scale and backyard chicken in Kenya*.* Gut Pathogens. 2016;8(1):1-9.
DOI: 10.1186/s13099-016-0121-5

45. Zhang X, Tang M, Zhou Q, Zhang J, Yang X, Gao Y. Prevalence and characteristics of *Campylobacter* throughout the slaughter process of different broiler batches*.* Frontiers in Microbiology. 2018;9:1-9.
DOI: 10.3389/fmicb.2018.02092

46. Bostan K, Aydın A, Kücüker Ang M. Prevalence and antibiotic susceptibility of thermophilic *Campylobacter* species on beef, mutton, and chicken carcasses in Istanbul, Turkey*.* Microbial Drug Resistance. 2009;15(2):143-149.

47. Dabiri H, Aghamohammad S, Goudarzi H, Noori M, Ahmadi Hedayati M, Ghoreyshiamiri SM. Prevalence and antibiotic susceptibility of *Campylobacter* species isolated from chicken and beef meat*.* Int J Enteric Pathog. 2014;2(2):1-4.

48. Brooks JT, Ochieng JB, Kumar L, Okoth G, Shapiro RL, Wells JG, Bird M, Bopp C, Chege W, Beatty ME. Surveillance for bacterial diarrhea and antimicrobial resistance in rural western Kenya, 1997–2003*.* Clinical Infectious Diseases. 2006; 43(4):393-401.

49. Shapiro RL, Kumar L, Phillips-Howard P, Wells JG, Adcock P, Brooks J, Ackers ML, Ochieng JB, Mintz E, Wahlquist S. Anti-microbial-resistant bacterial diarrhea in rural western Kenya*.* The Journal of Infectious Diseases. 2001;183(11):1701-1704.

50. Wei B, Cha SY, Kang M, Roh JH, Seo HS, Yoon RH, Jang HK. Antimicrobial susceptibility profiles and molecular typing of *Campylobacter jejuni* and *Campylobacter coli* isolated from ducks in South Korea*.* Applied and Environmental Microbiology. 2014;AEM-02469.

51. Kashoma IP, Kassem II, Kumar A, Kessy BM, Gebreyes W, Kazwala RR, Rajashekara G. Antimicrobial resistance and genotypic diversity of *campylobacter* isolated from pigs, dairy and beef cattle in Tanzania. Frontiers in Microbiology. 2015; 6:1-11.
DOI: 10.3389/fmicb.2015.01240

52. Gallay A, Prouzet-Mauléon V, Kempf I, Lehours P, Labadi L, Camou C, Denis M, De Valk H, Desenclos JC, Mégraud F*.* *Campylobacter* antimicrobial drug resistance among humans, broiler chickens, and pigs, France*.* Emerging Infectious Diseases. 2007;13(2):259-266.

DOI: 10.3201/eid1302.060587

53. Adzitey F, Rusul G, Huda N, Cogan T, Corry J. Prevalence, antibiotic resistance and RAPD typing of *Campylobacter* species isolated from ducks, their rearing and processing environments in Penang, Malaysia. International Journal of Food Microbiology. 2012;154(3):197-205.

54. Rahimi E, Alian F, Alian F. Prevalence and characteristic of *Campylobacter* species isolated from raw duck and goose meat in Iran. IPCBEE. 2011;9:171-175.

55. Nonga HE, Muhairwa AP. Prevalence and antibiotic susceptibility of thermophilic *Campylobacter* isolates from free range domestic duck (*Cairina moschata*) in Morogoro municipality, Tanzania. Tropical Animal Health and Production. 2010; 42(2):165-172.

56. Vlieghe ER, Jacobs JA, Van Esbroeck M, Koole O, Van Gompel A. Trends of norfloxacin and erythromycin resistance of *Campylobacter* jejuni/*Campylobacter* coli isolates recovered from international travelers, 1994 to 2006. Journal of Travel Medicine. 2008;15(6):419-425.

57. European Food Safety A, European Centre for Disease P, Control EU. Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2013. EFSA Journal. 2015;13(2):4036.

58. Van Looveren M, Daube G, De Zutter L, Dumont JM, Lammens C, Wijdooghe M, Vandamme P, Jouret M, Cornelis M, Goossens H. Antimicrobial susceptibilities of *Campylobacter* strains isolated from food animals in Belgium. Journal of Antimicrobial Chemotherapy. 2001;48(2): 235-240

59. Pezzotti G, Serafin A, Luzzi I, Mioni R, Milan M, Perin R. Occurrence and resistance to antibiotics of *Campylobacter jejuni* and *Campylobacter coli* in animals and meat in northeastern Italy. International Journal of Food Microbiology. 2003;82(3):281-287.

60. Wieczorek K, Osek J. Antimicrobial resistance mechanisms among *Campylobacter*. Bio Med Research International;2013.

61. Wang Y, Zhang M, Deng F, Shen Z, Wu C, Zhang J, Zhang Q, Shen J. Emergence of multidrug-resistant *Campylobacter* with a horizontally acquired ribosomal RNA methylase. Antimicrobial Agents and Chemotherapy. 2014;AAC-03039.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle3.com/review-history/49107